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Abstract
Background: Breast cancer mortality rates are 39% higher in the African- American 
(AA) women compared to White- American (WA) women despite the advances in 
overall breast cancer screening and treatments. Several studies have undertaken to 
identify the factors leading to this disparity in United States with possible effects of 
lower socioeconomic status and underlying aggressive biology.
Methods: A retrospective analysis was done using a prospectively maintained data-
base of a metropolitan health system. Patients were selected based on diagnosis of 
early- stage breast cancer between 10/1998 and 02/2017, and included women over 
age of 18 with clinically node- negative disease. Patients were then stratified by phe-
notype confirmed by pathology and patient- identified race.
Results: A total of 2,298 women were identified in the cohort with 39% AA and 61% 
WA women. The overall mean age at the time of diagnosis for AA women was slightly 
younger at 60 years compared to 62 years for WA women (p = 0.003). Follow- up 
time was longer for the WA women at 95 months vs. 86 months in AA women. The 
overall 5- year survival was analyzed for the entire cohort, with the lowest survival 
occurring in patients with triple- negative breast cancer (TNBC). Phenotype distribu-
tion revealed a higher incidence of TNBC in AA women compared to WA women (AA 
16% vs. WA 10%; p < 0.0001). AA women also had higher incidence of HER2 posi-
tive cancers (AA 16.8% vs. WA 15.3%; p < 0.0001). WA women had a significantly 
higher distribution of Non- TNBC/HER2- negative phenotype (AA 55% vs. WA 65%; 
p < 0.0001). Furthermore, a subgroup analysis was done for a sentinel lymph node 
(SLN) negative cohort that showed higher rates of grade 3 tumors in AA (AA 35% vs. 
WA 23%; p < 0.0001); and higher rates of grade 1 and grade 2 tumors in WA (30% vs. 
21% and 44% vs. 40%). Despite higher grade tumors in AA women, five- year overall 
survival outcomes in SLN- negative cohort did not differ between AA and WA women 
when stratifying based on tumor subtype.
Conclusion: Breast cancer survival disparities in AA and WA women with SLN- 
negative breast cancer are diminished when evaluated at early- stage cancers de-
fined by SLN- negative tumors. Our evaluation suggests that when diagnosed early, 
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1  |  INTRODUCTION
Despite a convergence of the population- based incidence rate 
of breast cancer between African- American (AA) and White- 
American (WA) women over the past decade, there has been a 
divergence in outcome disparities.1,2 Indeed, the current 5- year 
relative survival rate for WA and AA women is 92% and 83%, re-
spectively, with mortality rates 39% higher in AA women.3 And, 
while the incidence of breast cancer for the total population have 
equalized over the past decade, young AA women (≤40- years) 
continue to have higher incidence rates compared to similarly aged 
WA women.2
The survival disparity observed between WA and AA has been 
attributed to numerous factors, including later stage of diagnosis; 
socioeconomic factors (eg, delivery of care disparities and/or access 
to adequate healthcare); variation in treatment response; and/or an 
increased predisposition to develop biologically aggressive cancer 
phenotypes.2
In addition to poorer survival outcomes, AA women have a 
two- fold higher population- based incidence of aggressive tumor 
subtypes, including tumors that are negative for (1) the estrogen 
receptor; (2) the progesterone receptor; and (3) that do not overex-
press HER2/neu— otherwise known as triple- negative breast cancer 
(TNBC).4 Moreover, TNBC (80% of which belong to the inherently 
aggressive basal intrinsic subtype) are associated with poorer prog-
noses due to limited systemic therapy options.5
While the difference in TNBC survival rates between AA women 
and WA women has been investigated, these studies have yielded 
unsatisfying results with regard to identifying the underlying cause 
of the disparity. A study evaluating the effect of race on treatment 
showed no differences in pathologic response and survival outcomes 
between AA and WA when patients received similar treatment and 
follow- up for locally advanced TNBC breast cancer.6 Another study 
evaluating tumor biology of TNBC revealed no difference in treat-
ment response or biological profile between AA and WA women, 
demonstrating that survival disparities could not be attributed to 
tumor biology.7 Other studies have reported consistently lower 
breast cancer survival associated with AA women as an independent 
risk factor for survival compared to WA women after adjusting for 
tumor biology and treatment received.8,9
Because of the outcome disparities reported between AA and 
WA women, we sought to evaluate the survival rate and pheno-
type of patients with early- stage breast cancer with negative sen-
tinel lymph node (SLN) biopsy— a stage where opportunities for a 
favorable outcome is optimized— in order to determine whether the 
outcome disparities are a function of inadequate access to care and/
or underlying genetic predisposition.
2  | METHODS
A prospectively maintained, IRB- approved data base for patients 
with early- stage breast cancer with SLN biopsy was utilized for data 
collection. The data was collected from a hospital system, Henry 
Ford Health System, featuring a large employee- based health insur-
ance plan and serving a diverse community of the Metropolitan- 
Detroit area in Michigan.
The data was collected for women over 18 years old and diag-
nosed between 10/1998 (ie, around the date Tamoxifen became 
standard care) to 02/2017 with clinically early stage, node- negative 
breast cancer. Race and ethnicity identification were self- reported 
and collected during the initial encounter.
Tumor phenotype of each breast cancer was evaluated for 
hormone receptors, estrogen and progesterone, and HER2 status. 
Hormone receptor evaluation was performed via immunohisto-
chemistry for estrogen and progesterone receptors with invasive 
carcinoma positivity defined as any cell uptake >1%.10 Additional flu-
orescence in situ hybridization (FISH) was done for HER2 immunos-
taining for equivocal immunohistochemistry. TNBC was defined as 
negative in the absence of expression of estrogen, progesterone and 
HER2 markers. Non- TNBC with HER2- positive pathology was de-
fined as positive for estrogen and/or progesterone in the presence 
of a positive HER2 marker. Finally, Non- TNBC with HER2- negative 
was defined as the presence of positive estrogen and/or progester-
one markers, while showing an absence of expression of a negative 
HER2 marker. Pathological evaluation was also performed on the 
sentinel lymph nodes for local invasion of breast cancer. The median 
follow- up time was 60 months.
To determine the significant differences in clinicopathological 
variables between race groups, we used chi- square tests for cate-
gorical variables (ie, Hormone Receptor (HR) status and survival out-
comes) and two sample student's t- test for continuous variables (ie, 
age at diagnosis and survival times between race groups). The overall 
survival of all patients was censored at 5 year after diagnosis, and 
log- rank test was used to assess the difference in survival among 
groups. Kaplan- Meier plots were used for visualization. Additionally, 
a multivariate analysis was done to assess the variables risk jointly. 
Cox proportional Hazard models were deployed to assess the 
phenotype does not contribute to racial survival outcomes. The lower survival rate in 
AA women with breast cancer may be attributed to later stage biology between the 
two races, or underlying socioeconomic disparities.
K E Y W O R D
early- stage breast cancer
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association of survival with race, tumor subtypes, pathological grade 
and age at diagnosis jointly. All analyses were conducted using the R 
statistical programming version 3.6.1.
3  |  RESULTS
A total of 2,298 women were identified in the cohort. The popula-
tion breakdown consists of 39% of AA women (n = 907) and 61% WA 
women (n = 1,391). Both groups had a similar proportion of negative 
SLN biopsy (AA 46% vs. WA 52%; p = 0.509). The overall mean age at 
the time of diagnosis for AA women was 60 years old, and 62 years 
old for WA women (p = 0.003). Follow- up time in months was longer 
for the WA women at 95 months vs. 86 months in AA women. SLN 
biopsy results were evaluated for 58% of AA women, and 66% of 
WA women (SLN biopsy results were unavailable in the remaining 
unscored AA women and WA women). There was no significance 
demonstrated between SLN positive and negative cohorts between 
the two races (Table 1).
The overall 5- year survival was analyzed for the entire cohort, 
with the lowest survival occurring in patients with TNBC, followed 
by Non- TNBC/HER2- positive. The best survival outcomes were 
observed in patients with the Non- TNBC/HER2- negative pheno-
type (Figure 1). In the multivariable cox proportional hazard model-
ing where age at diagnosis, pathological T grade, and self- reported 
race were adjusted, TNBC remains at highest risk compared with 
Non- TNBC/HER2- positive and Non- TNBC/HER2- negative patients 
(Supplementary Table S1).
Phenotype distribution revealed a higher incidence of TNBC 
in AA women compared to WA women (AA 16% vs. WA 10%; 
p < 0.0001) (Table 1). AA women also had slightly higher incidence 
of Non- TNBC/HER2- positive phenotype (AA 16.8% vs. WA 15.3%; 
p < 0.0001). Furthermore, WA women had a significantly higher dis-
tribution of Non- TNBC/HER2- negative phenotype (AA 55% vs. WA 
65%; p < 0.0001).
There were significant differences in the incidence of SLN- 
negative breast cancer when stratifying based on race and pheno-
type (Table 2). While AA had a lower incidence of the Non- TNBC/
HER2- negative phenotype than WA women (AA 54% vs. WA 65%; 
p = 0.0002), there was a higher incidence in AA women for both the 
Non- TNBC/HER2- positive tumors (AA 14% vs. WA 13%; p = 0.0002) 
and TNBC phenotypes (AA 17% vs. WA10%; p < 0.0001) (Table 2). 
Finally, no differences were found when comparing age at diagnosis 
and follow- up times between the two races (Table 2).
The AA SLN- negative patients had a higher rate of tumor grade 3 
at diagnosis (AA 35% vs. WA 23%; p < 0.0001) (Table 2). In contrast, 
WA SLN- negative women had higher rates of grade 1 and 2 tumors 
(30% vs. 21% and 44% vs. 40%) (Table 2). Surprisingly, there was 
no difference observed in the survival probability for early stage, 
SLN- negative patients when stratified based on tumor phenotype 
(Figure 2). The five- year overall survival outcome between AA 
and WA women with SLN- negative breast cancer, and when strat-
ifying based on tumor subtype, showed no significant difference 
(Figures 3– 5). Similarly, despite a lower five- year overall survival in 
AA women compared to WA women, this difference was not found to 
be significant in the SLN- negative patients (Figure 3). Furthermore, 
multivariable analysis adjusting for age at diagnosis and pathological 
T stage was completed to evaluate for possible effects of the race 
and phenotype subtypes (Supplementary Tables: S2– S5). No addi-
tional statistical significance was found in this analysis.
4  |  CONCLUSION
AA women have been shown to have a significantly lower overall 
survival rate than WA women during all stages of breast cancer, 
especially when they have received a late- stage diagnosis.2 And, 
despite numerous studies evaluating the underlying biological dif-
ferences, socioeconomic factors (eg, access to care), and/or delay in 
diagnosis, the cause of the overall survival disparity remains unclear.
Regardless of race, both AA women and WA women with 
TNBC exhibit significantly lower survival rates compared to those 
with HER2- overexpressing and/or hormone receptor- positive 
disease.11 TNBC is known to occur at a higher rate in AA women, 
specifically premenopausal AA women in population- based stud-
ies.12- 15 Accordingly, the higher incidence of TNBC in AA women 
has been evaluated as a contributing factor to lower survival in AA 
women. Furthermore, when evaluating racial disparities in cancer 
survival with controls for stage, socioeconomic variable, tumor 
biology and treatment patterns, AA women possess an overall 
lower survival for breast cancer in both endocrine- responsive and 
TA B L E  1  Distribution of all variables in the entire cohort
Features AA (n = 907)
WA 
(n = 1,391) p- value
Sentinel lymph node biopsy status
Negative 420 (46.3%) 727 (52.3%) 0.509
Positive 102 (11.2%) 195 (14.0%)
Missing 385 (42.4%) 469 (33.7%)
Subtype
Non- TNBC (Her2- ) 494 (54.5%) 905 (65.1%) <0.0001
Non- TNBC (Her2+) 152 (16.8%) 213 (15.3%)
TNBC 141 (15.5%) 145 (10.4%)
Missing 120 (13.2%) 128 (9.2%)
Tumor grade
1 189 (20.8%) 370 (26.6%) <0.0001
2 371 (40.9%) 639 (45.9%)
3 304 (33.5%) 348 (25.0%)
Missing 43 (4.8%) 34 (2.4%)
Age, Years (mean, 
range)
60.1 (21,92) 61.6 (23,91) 0.003
Follow- up time, 
Months (mean, 
range)
85.8 (3,218) 95.3 (0,218) 0.0001
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endocrine- unresponsive early- stage breast cancer.9Here, we iden-
tified possible pathologic trends in early- stage breast cancer that 
could account for the known disparities in survival between the AA 
and WA women with breast cancer.1,2 Breast cancer survival dispar-
ities between AA and WA women with SLN- negative breast cancer 
are diminished when accounting for tumor phenotype (Figure 2). 
Moreover, the results presented here suggest that TNBC, when di-
agnosed early, does not result in a disparate survival outcome be-
tween AA and WA women (Figure 3). Accordingly, this study shows 
that the overall lower survival rate in AA women with TNBC may be 
F IGURE  1 Five- year overall survival 
stratified by breast cancer subtypes in the 
entire cohort.
Tumor Subtype 5-year survival probability 95%CI
Non-TNBC(Her2-) 0.90 0.89-0.92
Non-TNBC (Her2+) 0.89 0.86-0.93
TNBC 0.82 0.77-0.87
Features AA WA p- value
Tumor subtype
Non- TNBC (Her2- ) 224 (53.3%) 475 (65.3%) 0.0002
Non- TNBC (Her2+) 60 (14.3%) 95 (13.1%)
TNBC 72 (17.1%) 73 (10.0%)
Missing 64 (15.2%) 84 (11.6%)
Grade
1 89 (21.19%) 224 (30.81%) <0.0001
2 170 (40.48%) 322 (44.29%)
3 148 (35.24%) 170 (23.38%)
Missing 13 (3.10%) 11 (1.51%)
Age, Years (mean, range) 60.4 (27,92) 61.8 (31,91) 0.062
Follow- up time, Months (mean, 
range)
116 (3,218) 121 (1,214) 0.130
TA B L E  2  Distribution of variables in 
SLN- negative patients
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attributable to factors other than underlying genetic or biological 
factors, for example, later presentation for diagnosis and/or access 
to care.
Within the entire cohort, AA women had a higher incidence of 
TNBC compared to WA women; this difference became more pro-
nounced when isolating for SLN- negative patients (ie, 17% in AA vs. 
10% in WA; Table 2). These results would seem to suggest that AA 
women have a biological predisposition to the TNBC phenotype; 
thus, one would expect to find a lower survival rate for SLN- negative 
AA women with TNBC. However, when analyzing the overall sur-
vival outcome of AA and WA women, there was no significant dif-
ference between the two groups (Figure 3). Consequently, the lack 
of outcome disparity observed here between AA and WA women 
with SLN negative, TNBC could be attributable to some nonbiolog-
ical factor such as socioeconomic disparities (eg, reduced access to 
care) and/or later presentation for diagnosis, incomplete therapy, or 
decreased access to follow- up.
Alternatively (and notwithstanding experimental design flaws, 
eg, sample size, etc.), the disparate survival outcome shown for the 
overall cohort, but absent when isolating based on SLN- negativity, 
could be attributable to biological differences observed at later 
stages between WA and AA patients. However, it is worth noting 
that the results of this study concur with similar studies evaluating 
the effect of race on TNBC. Alcantara et al. evaluated the incidence 
and prognosis of TNBC among Chinese, Malay, and Indian patients 
and found that race/ethnicity did not impact TNBC prognosis.16 
Likewise, recent studies have shown that the mutational landscape 
between AA women and WA women with TNBC is similar.17
Finally, the differences observed in median survival between AA 
and WA patients— within the strata of HER2- overexpressing and/
or hormone receptor- positive disease— suggest the possible influ-
ence of compliance/access to targeted therapy and/or differences 
in response to targeted therapy. In other studies, evaluating treat-
ment effects and outcomes between AA and WA have shown more 
pronounced disparities in overall and disease- free survival among 
estrogen- positive AA women.18- 20 However, in this retrospec-
tive study, a larger proportion of AA were included in the sample 
with a wider inclusion criteria (ie, not excluding patients based on 
comorbidities)— which is more reflective of the general AA popula-
tion. However, in light of differences in our findings compared to 
other studies based on hormone positive outcomes, further pro-
spective studies would be vital to determine underlying racial differ-
ences that could contribute/suggest to different biological response 
or perhaps decreased compliance.
F IGURE  2 Five- year overall survival 
by phenotype in SLN- negative breast 
cancers
6  |    LEHRBERG Et aL.
This study is limited by its retrospective and nonrandomized 
study design. As such, it is subject to misclassification and selection 
bias. Furthermore, our database has limited information on type of 
adjuvant chemotherapy which could contribute to cancer response 
based on race as well as agents used as suggested by other studies 
by Schneider, Sparano and Tichy.18,19,21 Moreover, despite being a 
multi- center study in the state of Michigan, conclusions may not be 
directly generalizable to other institutions or geographical locations.
Finally, in conclusion, stratifying patients based on stage (ie, 
SLN- negative, or early breast cancer analysis) reveals no difference 
with regard to survival outcome between AA and WA women based 
on tumor phenotype. This significant finding suggests that either 
F IGURE  3 Five- year overall 
survival by race in TNBC SLN- negative 
patients
F IGURE  4 Five- year overall survival in 
Non- TNBC/Her2- positive SLN- negative 
patients
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later stage biology differs between the two races, or the access and 
medical treatment diverges due to factors such as access to treat-
ment; this finding is important because other studies have shown 
that TNBC and HER2+ cancer in AA women had worse survival 
compared to WA women. Accordingly, further inquiry is required to 
determine whether earlier or more rigorous screening and/or bet-
ter follow- up procedures have an effect on outcome disparities be-
tween AA and WA women with breast cancer.
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